Product Information
Registration Status: ActiveSANDOSTATIN INJECTION 0.1mg/ML is approved to be sold in Singapore with effective from 1990-01-02. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN03808P.
This product contains Octreotide 0.1mg/ml in the form of INJECTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by NOVARTIS PHARMA AG
NOVARTIS PHARMA AG in SWITZERLAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.
Indication
For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Mechanism of Action
Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
Clearance
* 7 – 10 L/hr [healthy after 100-mcg SC injection] * 18 L/hr [patients with acromegaly after 100-mcg SC injection] * 8.8 L/hr [mild renal impairment after 100-mcg SC injection] * 7.3 L/hr [moderate renal impairment after 100-mcg SC injection] * 7.6 L/hr [severe renal impairment after 100-mcg SC injection] * 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection] * 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection] * 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]
Active Ingredient/Synonyms
Octreotida | Octreotidum | Octrotide | Octreotide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.